1
WGU D116 ADVANCED PHARMACOLOGY FINAL OA EXAM
2026/2027 | Actual Exam & Practice Exam Latest | Complete
Questions & Correct Answers | Already Graded A+ | Pass
Guaranteed
ACTUAL FINAL OA EXAM - 80 QUESTIONS - ALREADY GRADED A+
[OA1: Core Pharmacokinetic & Pharmacodynamic Principles (Q1-12)]
Q1. Phenytoin exhibits nonlinear (Michaelis-Menten) pharmacokinetics. Which clinical
implication is most important for a nurse practitioner managing a patient whose
phenytoin dose is increased from 300 mg/day to 400 mg/day?
A. A 33% dose increase will produce a proportional 33% increase in serum
concentration.
B. Small dose increases can produce disproportionately large increases in serum
concentration due to enzyme saturation.
C. The drug's half-life will shorten as the dose increases.
D. Tissue redistribution will prevent any significant change in serum levels.
Correct Answer: B. Small dose increases can produce disproportionately large
increases in serum concentration due to enzyme saturation. [CORRECT]
Rationale: Phenytoin follows Michaelis-Menten kinetics; once CYP2C9/2C19 enzymes
approach saturation, small dose increments cause large serum concentration jumps,
increasing toxicity risk. Option A describes linear kinetics. Option C is incorrect because
saturation prolongs half-life. Option D is incorrect because tissue redistribution does
not prevent serum level changes in nonlinear kinetics. (Source: Nonlinear
Pharmacokinetics, Phenytoin TDM)
Correct Answer: B
,2
Q2. A patient on theophylline for COPD develops a respiratory infection and is
prescribed ciprofloxacin. The nurse practitioner recognizes that ciprofloxacin is a
CYP1A2 inhibitor. What is the primary clinical concern with this combination?
A. Theophylline metabolism will increase, causing therapeutic failure.
B. Theophylline levels may rise significantly, increasing the risk of toxicity (nausea,
arrhythmias, seizures).
C. Ciprofloxacin absorption will be reduced by theophylline.
D. The combination produces a synergistic bronchodilator effect that requires dose
reduction.
Correct Answer: B. Theophylline levels may rise significantly, increasing the risk
of toxicity (nausea, arrhythmias, seizures). [CORRECT]
Rationale: Theophylline is metabolized by CYP1A2; ciprofloxacin inhibits this enzyme,
reducing clearance and increasing serum theophylline levels, which can precipitate
toxicity (nausea, vomiting, cardiac arrhythmias, seizures). Option A is incorrect because
metabolism decreases, not increases. Option C is incorrect because theophylline does
not reduce ciprofloxacin absorption. Option D is incorrect because there is no
synergistic bronchodilation requiring reduction. (Source: CYP1A2 Drug Interactions,
Theophylline Toxicity)
Correct Answer: B
Q3. Which pharmacokinetic process describes the cycling of a drug from the liver to the
intestine via bile, followed by reabsorption from the intestinal lumen back into
circulation?
A. First-pass metabolism
B. Enterohepatic recirculation
C. Tissue redistribution
D. Glomerular filtration
Correct Answer: B. Enterohepatic recirculation [CORRECT]
Rationale: Enterohepatic recirculation is the process where drugs conjugated in the
liver are excreted in bile, deconjugated by gut flora, and reabsorbed, prolonging drug
,3
half-life (e.g., ethinyl estradiol, some statins). First-pass metabolism (A) is hepatic
metabolism before systemic circulation. Tissue redistribution (C) involves drug
movement from plasma to tissues. Glomerular filtration (D) is renal excretion. (Source:
Pharmacokinetics, Enterohepatic Circulation)
Correct Answer: B
Q4. A patient who is a CYP2D6 ultra-rapid metabolizer receives codeine for
postoperative pain. What is the primary clinical risk?
A. Codeine will be ineffective due to rapid elimination.
B. Codeine will be rapidly converted to morphine, potentially causing severe respiratory
depression and overdose.
C. The patient will experience excessive histamine release from codeine.
D. CYP2D6 ultra-rapid metabolism prevents codeine absorption.
Correct Answer: B. Codeine will be rapidly converted to morphine, potentially
causing severe respiratory depression and overdose. [CORRECT]
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine
for analgesic effect. Ultra-rapid metabolizers convert codeine to morphine excessively
fast, causing life-threatening respiratory depression. Option A describes poor
metabolizers. Option C describes a non-CYP2D6-related effect. Option D is
pharmacokinetically impossible. (Source: Pharmacogenomics, CYP2D6, FDA Codeine
Black Box Warning)
Correct Answer: B
Q5. Which pharmacodynamic concept explains why a patient requires progressively
higher doses of an opioid to achieve the same analgesic effect over time?
A. Pharmacokinetic tolerance
B. Pharmacodynamic tolerance via receptor downregulation or desensitization
, 4
C. Allosteric modulation
D. Biased agonism
Correct Answer: B. Pharmacodynamic tolerance via receptor downregulation or
desensitization [CORRECT]
Rationale: Pharmacodynamic tolerance occurs when repeated opioid exposure causes
mu-opioid receptor downregulation, desensitization, or internalization, reducing drug
effect and requiring dose escalation. Pharmacokinetic tolerance (A) involves increased
metabolism. Allosteric modulation (C) and biased agonism (D) are receptor mechanisms
unrelated to tolerance development. (Source: Pharmacodynamics, Receptor Regulation,
Opioid Tolerance)
Correct Answer: B
Q6. A drug acts as an allosteric modulator at a GABA-A receptor. Which statement best
describes its mechanism of action?
A. It binds to the orthosteric site and fully activates the receptor.
B. It binds to a secondary site distinct from the endogenous ligand site, enhancing or
inhibiting receptor response.
C. It blocks the receptor completely, preventing any GABA binding.
D. It functions as a competitive antagonist at the GABA binding site.
Correct Answer: B. It binds to a secondary site distinct from the endogenous
ligand site, enhancing or inhibiting receptor response. [CORRECT]
Rationale: Allosteric modulators bind to regulatory sites distinct from the orthosteric
(primary) ligand site, altering receptor conformation and response to the endogenous
agonist (e.g., benzodiazepines at GABA-A receptors). Option A describes orthosteric
agonism. Option C describes non-competitive antagonism. Option D describes
competitive antagonism. (Source: Pharmacodynamics, Allosteric Modulation)
Correct Answer: B
WGU D116 ADVANCED PHARMACOLOGY FINAL OA EXAM
2026/2027 | Actual Exam & Practice Exam Latest | Complete
Questions & Correct Answers | Already Graded A+ | Pass
Guaranteed
ACTUAL FINAL OA EXAM - 80 QUESTIONS - ALREADY GRADED A+
[OA1: Core Pharmacokinetic & Pharmacodynamic Principles (Q1-12)]
Q1. Phenytoin exhibits nonlinear (Michaelis-Menten) pharmacokinetics. Which clinical
implication is most important for a nurse practitioner managing a patient whose
phenytoin dose is increased from 300 mg/day to 400 mg/day?
A. A 33% dose increase will produce a proportional 33% increase in serum
concentration.
B. Small dose increases can produce disproportionately large increases in serum
concentration due to enzyme saturation.
C. The drug's half-life will shorten as the dose increases.
D. Tissue redistribution will prevent any significant change in serum levels.
Correct Answer: B. Small dose increases can produce disproportionately large
increases in serum concentration due to enzyme saturation. [CORRECT]
Rationale: Phenytoin follows Michaelis-Menten kinetics; once CYP2C9/2C19 enzymes
approach saturation, small dose increments cause large serum concentration jumps,
increasing toxicity risk. Option A describes linear kinetics. Option C is incorrect because
saturation prolongs half-life. Option D is incorrect because tissue redistribution does
not prevent serum level changes in nonlinear kinetics. (Source: Nonlinear
Pharmacokinetics, Phenytoin TDM)
Correct Answer: B
,2
Q2. A patient on theophylline for COPD develops a respiratory infection and is
prescribed ciprofloxacin. The nurse practitioner recognizes that ciprofloxacin is a
CYP1A2 inhibitor. What is the primary clinical concern with this combination?
A. Theophylline metabolism will increase, causing therapeutic failure.
B. Theophylline levels may rise significantly, increasing the risk of toxicity (nausea,
arrhythmias, seizures).
C. Ciprofloxacin absorption will be reduced by theophylline.
D. The combination produces a synergistic bronchodilator effect that requires dose
reduction.
Correct Answer: B. Theophylline levels may rise significantly, increasing the risk
of toxicity (nausea, arrhythmias, seizures). [CORRECT]
Rationale: Theophylline is metabolized by CYP1A2; ciprofloxacin inhibits this enzyme,
reducing clearance and increasing serum theophylline levels, which can precipitate
toxicity (nausea, vomiting, cardiac arrhythmias, seizures). Option A is incorrect because
metabolism decreases, not increases. Option C is incorrect because theophylline does
not reduce ciprofloxacin absorption. Option D is incorrect because there is no
synergistic bronchodilation requiring reduction. (Source: CYP1A2 Drug Interactions,
Theophylline Toxicity)
Correct Answer: B
Q3. Which pharmacokinetic process describes the cycling of a drug from the liver to the
intestine via bile, followed by reabsorption from the intestinal lumen back into
circulation?
A. First-pass metabolism
B. Enterohepatic recirculation
C. Tissue redistribution
D. Glomerular filtration
Correct Answer: B. Enterohepatic recirculation [CORRECT]
Rationale: Enterohepatic recirculation is the process where drugs conjugated in the
liver are excreted in bile, deconjugated by gut flora, and reabsorbed, prolonging drug
,3
half-life (e.g., ethinyl estradiol, some statins). First-pass metabolism (A) is hepatic
metabolism before systemic circulation. Tissue redistribution (C) involves drug
movement from plasma to tissues. Glomerular filtration (D) is renal excretion. (Source:
Pharmacokinetics, Enterohepatic Circulation)
Correct Answer: B
Q4. A patient who is a CYP2D6 ultra-rapid metabolizer receives codeine for
postoperative pain. What is the primary clinical risk?
A. Codeine will be ineffective due to rapid elimination.
B. Codeine will be rapidly converted to morphine, potentially causing severe respiratory
depression and overdose.
C. The patient will experience excessive histamine release from codeine.
D. CYP2D6 ultra-rapid metabolism prevents codeine absorption.
Correct Answer: B. Codeine will be rapidly converted to morphine, potentially
causing severe respiratory depression and overdose. [CORRECT]
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine
for analgesic effect. Ultra-rapid metabolizers convert codeine to morphine excessively
fast, causing life-threatening respiratory depression. Option A describes poor
metabolizers. Option C describes a non-CYP2D6-related effect. Option D is
pharmacokinetically impossible. (Source: Pharmacogenomics, CYP2D6, FDA Codeine
Black Box Warning)
Correct Answer: B
Q5. Which pharmacodynamic concept explains why a patient requires progressively
higher doses of an opioid to achieve the same analgesic effect over time?
A. Pharmacokinetic tolerance
B. Pharmacodynamic tolerance via receptor downregulation or desensitization
, 4
C. Allosteric modulation
D. Biased agonism
Correct Answer: B. Pharmacodynamic tolerance via receptor downregulation or
desensitization [CORRECT]
Rationale: Pharmacodynamic tolerance occurs when repeated opioid exposure causes
mu-opioid receptor downregulation, desensitization, or internalization, reducing drug
effect and requiring dose escalation. Pharmacokinetic tolerance (A) involves increased
metabolism. Allosteric modulation (C) and biased agonism (D) are receptor mechanisms
unrelated to tolerance development. (Source: Pharmacodynamics, Receptor Regulation,
Opioid Tolerance)
Correct Answer: B
Q6. A drug acts as an allosteric modulator at a GABA-A receptor. Which statement best
describes its mechanism of action?
A. It binds to the orthosteric site and fully activates the receptor.
B. It binds to a secondary site distinct from the endogenous ligand site, enhancing or
inhibiting receptor response.
C. It blocks the receptor completely, preventing any GABA binding.
D. It functions as a competitive antagonist at the GABA binding site.
Correct Answer: B. It binds to a secondary site distinct from the endogenous
ligand site, enhancing or inhibiting receptor response. [CORRECT]
Rationale: Allosteric modulators bind to regulatory sites distinct from the orthosteric
(primary) ligand site, altering receptor conformation and response to the endogenous
agonist (e.g., benzodiazepines at GABA-A receptors). Option A describes orthosteric
agonism. Option C describes non-competitive antagonism. Option D describes
competitive antagonism. (Source: Pharmacodynamics, Allosteric Modulation)
Correct Answer: B
